References
- Lock GR, Tally NJ, Fett SL, et al. Preva-lence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterol 1997;112:1448–56.
- Ronkainen J, Aro P, Storskrubb T, et al. Prevalence of oesophagitis and endoscopy-negative reflux disease in a population. A report from the Kalixanda Study. Gastroenterol 2002;122(4) (Suppl1):A213.
- Holtmann G, Goebell H, Tally NJ. Dyspepsia in consulters and non-consulters: prevalence, health-care seeking behaviour and risk factors. European J Gastroenterology and Hepatology 1994;6:917–24.
- Quigley EM. Non-erosive reflux disease: part of the spectrum of gastro-oesophageal reflux disease, a component of functional dyspepsia, or both? Eur J Gastroenterol Hepatol 2001; 13(Suppl1): S13–8.
- Talley NJ, Stanghellini V, Heading RC et al., Functional gastroduodenal disorders. Rome Functional Gastrointestinal Disorders 2000; 299–350.
- Tally NJ, Weaver AL, Tesmer DL. Lack of discriminant value of dyspepsia subgroups in patients referred for upper endoscopy. Gastroenterol 1993;105:1378–86.
- Dent J, Brun J, Fennerty MB, et al. An evidence-based appraisal of reflux disease management—the Genval Workshop Report. Gut 1999;44(Suppl2): S1–16.
- Kang JY, Tinto A, Higham J, et al. Peptic ulceration in England and Wales 1994–98: period prevalence and drug management. Aliment Pharmacol and Therapeutics 2002;16:1067–74.
- Tally NJ, Meineche-Schmidt V, Pare P, et al. Efficacy of omeprazole in functional dyspepsia: double-blind placebo—controlled trials (the Bond and Opera studies). Aliment Pharmacology and Therapeutics 1998;1 2:1055–65.
- Moayyedi P, Deeks J, Tally NJ, et al. An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews. Am J Gastroenterol 2003;98:2621–6.
- Numans ME, Lau J, De Wit NJ, et al. Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics. Scand J Gastroenterol 2003:38(12): 1200–3.
- Johnsson F, Hattleback JG, Klintenberg AC, et al. Scand J Gastroenterol 2003; 38(4): 354–9.
- Juul-Hansen P, Rydnlng A. Endoscopy- negative reflux disease: what is the value of a proton-pump inhibitor test in everyday clinical practice? Am J Gastroenterol 2004; 99(6): 981–8.
- Inadomi JM, McIntyre L, Bernard L, et al. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs. J Clin Gastroenterol 2004; 38(1): 24–9.
- Meineche-Schmidt V. Empiric treatment with high and standard dose of omeprazole in general practice: two-week randomised placebo-controlled trial and 12-month follow-up of health-care consumption. Am J Gastroenterol 2004; 99(6): 1050–8.
- Gerson LB, Robbins AS, Garber A, et al. A cost-effective analysis of prescribing strategies in the management of gastroesophageal reflux disease. Am J Gastroenterol 2000; 95(2): 395–407.
- Bytzer R, Blum AL. Personal view: rationale and proposed algorithms for symptom- based proton pump Inhibitor therapy for gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2004;20:389–98.